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1. Introduction 
The identification of the species that comprise the Mycobacterium genus is one of the best 
documented examples of scientific development and technology. Approximately 150 species 
are currently recognized that, besides comprising a genus because of structural and 
biochemical similarities, exhibit a great variety of characteristics that permit the 
establishment of differential patterns in order to identify and characterize them, or to 
establish clusters or complexes. At the present time it is insufficient for the performance of 
tests that would determine if a given specie belongs to the Mycobacterium genus. There is 
clearly a pressing need to establish its membership in a group or complex, and to determine 
its specie and genetic characterization so as to permit a comparison of characteristics such as 
frequency and distribution at a global level. 
Within this bacterial genus appear species that, for their public health impact, have been 
extensively studied; this is in contrast with those that have been recently identified, or of 
limited frequency, and of which only general characteristics are known.  
These species share conventional microbiological methodologies that are based on the 
classification made by Dr. Runyon in designating them as photochromogens, 
scotochromogens, and non-chromogens, depending on their capacity, or inability, to 
synthesize pigments with or without light stimulus. Other characteristics, such as the speed 
of growth, have been used in differentiation through a wide variety of biochemical tests. The 
development of molecular biology contributes to the identification and characterization of 
species in only one test, thus requiring less time, and promotes the process of biosecurity as 
it does not necessitate a live microorganism beyond the initial steps of each experimental 
protocol. The advance of the science is evidenced through the adoption of recent 
methodologies that quantify volatile compounds through the odors of a patient or from 
certain clinical specimens; the use of nanoparticles and mass spectrometry appear to be the 
most promising developments for the very near future.  
In conclusion, the analysis and documentation demonstrate that we do not yet possess the 
ideal methodology for the identification of mycobacteria. The most promising outlook for 
the identification of the species that comprise the Mycobacterium genus can be found in the 
recognition of its biochemical characteristics; the use of conventional methodologies; an 
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appreciation of the techniques of molecular biology in its contribution to science and the 
mitigation of human suffering, while being reasonable in its use; and an unceasing 
advancement toward the development and implementation of new methodologies 
produced through scientific, technical, and social advancement.  
2. Phenotypic identification 
The phenotypic identification of mycobacteria is based on the characteristics of the culture 
and biochemical features, and comprises a large variety of tests, some of which are 
conducted in order to locate the microorganisms into two large groups: 
1. Species that comprise the Mycobacterium tuberculosis complex: to date, it has been 
reported that 9 species are included in this complex and, as the species are closely-
related genetically, occasionally the phenotypic methodologies are unable to 
discriminate among some of the species, being able to determine only membership in 
the M. tuberculosis complex (Brosch et al 2002).  
M. tuberculosis, as a causal agent of tuberculosis, is the species with the greatest world-
wide distribution. The other species that comprise this complex are: M. bovis, M. 
africanum, Bacille Calmette- Guerín (BCG) vaccine strain, M. microti, M. cannetti, M. caprae, 
M. pinnipedii, and M. mungi. 
The following tests and phenotypic observations identify this complex: velocity of 
growth; colony morphology; pigment production; niacin test; nitrate reduction; catalase 
activity; formation of the cord factor; urease test; pyrazinamidase test; growth in the 
presence of p-nitrobenzoic acid; and, growth in the presence of hydrazide of thiophene-
2-carboxylic acid. 
2. Non-Tuberculous Mycobacteria (NTM): reports indicate that about 140 species have 
been documented, with similar phenotypic characteristics; a large number of 
biochemical tests, in different culture media, are needed for identification and 
observation of the growth of the microorganism; various molecules are added to the 
culture to highlight the differential characteristics among the species that comprise the 
Mycobacterium genus. These tests should be conducted in conjunction with tests that 
identify the M. tuberculosis complex in order to guarantee an adequate analysis of 
identification.  
3. M. leprae: is a non-cultivable species. 
The fundamentals of each test used in the identification of mycobacteria are described as 
follows: 
2.1 Characteristics deduced from the direct observation of a culture medium, or 
growth inhibition, and microscopic observation 
2.1.1 Velocity of growth 
Mycobacteria are grouped according to velocity of growth as either slow or rapid growth. 
mycobacteria that develop colonies, visible by eyesight, in a culture medium in less than 7 
days are classified as rapid growth; those requiring more than 7 days in which to form 
visible colonies are designated as slow growth. The rRNA comprises 80% of the RNA of 
mycobacteria and one unit of its DNA. The RNA produced depends upon the number of rrn 
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operons and the efficiency of their transcription. One or two rrn operons are found in 
mycobacteria, regulated by P1 and P2 promoters. The rrnA operon, located in the murA gene, 
is found in all species, including M. tuberculosis and M. leprae; but, in some species, like those 
of rapid growth, an additional rrnB operon is found, located in the tyrS gene (Arnvig et al. 
2005, Verma et al 1999). 
2.1.2 Colony morphology 
Mycobacteria in culture generally appear as two types of colonies: rough or smooth, and 
with a shiny or opaque aspect (Tasso et al 2003). 
2.1.3 Pigment 
Some species of mycobacteria, classified as photochromogens, produce carotenoid pigment 
in the presence of light; the group designated as scotochromogenic develops yellow colonies 
independent of light stimulus; the non-chromogenic group does not produce pigment; their 
colonies appear with shades of pale yellow or cream, in the presence of light or in darkness, 
and the color does not intensify when exposed to light (Bernardelli et al 2007, Belén et al 
2007). 
2.1.4 Growth in presence of P-nitrobenzoic acid 
This test contributes to the differentiation of species of the M. tuberculosis complex. P-
nitrobenzoic acid inhibits the growth of: M. tuberculosis, M. bovis, M. africanum, and M. 
microti (Palomino et al 2007). 
2.1.5 Growth in the presence of hydrazide of thiophene-thiophene-2-carboxilic acid 
Permits the differentiation of M. tuberculosis that grows in the presence of the compound as 
opposed to other species such as M. bovis; it is sensitive to the compound when added to the 
Lowenstein Jensen (LJ) medium. Some species of NMT are positive for this test. 
2.1.6 Growth in McConkey agar without violet crystal 
Mycobacteria such as M. fortuitum, M. chelonae, and M. abscessus have the ability to grow in 
McConkey agar without violet crystal, as opposed to other mycobacteria such as M. 
tuberculosis and M. bovis that cannot grow in this medium. 
2.1.7 Growth in 5% sodium chloride 
Species of mycobacteria such as M. fortuitum show the capacity to grow in a LJ culture 
medium to which has been added 5% sodium chloride.  
2.1.8 Growth in the presence of hydroxylamine 
This test plays a very important role in determining the difference in capacity of growth of 
species such as M. bovis in LJ media supplemented with a concentration of 250 mg of 
hydroxylamine. NTM does not have this capability.  
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2.1.9 Growth in Sauton picric medium and Sauton agar with 0.2% picric acid 
This test is fundamental to differentiate mycobacteria of slow and rapid growth. 
Mycobacteria of rapid growth, with the exception of M. chelonae, have the capacity to grow 
in this medium. Among mycobacteria of slow growth, M. simie is unable to grow in this 
medium.  
2.1.10 Cord formation in acid-alcohol resistant bacilli 
This involves demonstrating the capacity to form cords from aggregates of acid-alcohol 
resistant bacilli in which the longitudinal axis of the bacteria is parallel to the longitudinal 
axis of the cord (Tasso et al 2003). This characteristic is attributed to glycolipid trehalose 6,6-
dimycolate or cord factor, which is composed of molecules of mycolic acids (Palomino et al 
2007). The presence of the cord in Ziehl Neelsen (ZN) coloration from rough, non-
chromogenic colonies is indicative of the presence of M. tuberculosis; on the contrary, the 
absence of a cord, or the uniform distribution of bacilli, is consistent with NTM (Tasso et al 
2003). 
2.2 Biochemical test of identification  
2.2.1 Niacin test 
Niacin is part of the energy metabolism of mycobacteria in redox reactions. All mycobacteria 
produce niacin, but M. tuberculosis accumulates it as a result of the major activity of Nicotinamide 
Adenine Dinucleotide and the inability to process the resulting Niacine (Palomino et al 2007, 
Cardoso et al 2004)). The test demonstrates the presence of cyanogen chloride formed through 
the reaction of chloramine T and potassium thiocyanate in the presence of citric acid. The 
cyanogen chloride breaks the pyridine ring of niacin, forming the aldehyde gamma-
carboxyglutamate that binds with the aromatic amine producing a yellow color. 
2.2.2 Nitrate reduction test 
Nitrate reductase, an enzyme capable of reducing nitrates to nitrites, appears in the cellular 
membranes of mycobacteria; the bacteria can utilize this enzyme as a source of nitrogen 
(Palomino et al 2007). The test detects the presence of nitrate reductase in a medium that 
contains sodium nitrate. The enzyme reduces nitrate to nitrite that appears through the 
addition of sulfalinamide and dihydrochloride –N- naphtyl ethylendiamine, forming a 
complex of diazonium chloride with a fuchsia color ( Bernardelli et al 2007). 
2.2.3 Catalase test 
This is an antioxidant enzyme responsible for eliminating molecules of hydrogen peroxide 
from the cells that are produced during respiration. The reaction results in the release of 
water and free oxygen (Palomino et al 2007). Two classes of catalase, thermolabile and 
thermostable, appear in mycobacteria. In M. tuberculosis and M. bovis the enzymatic activity 
is inhibited at 68°C; this contrasts with the remaining species of mycobacteria that maintain 
enzymatic activity following the increase in temperature (Organización Panamericana de la 
Salud 2008). Oxygen in the form of bubbles, caused by the activity of the enzyme in a 
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solution of perhydrol 30% and Tween 80 at 10%, appears during the test. The height of the 
column of bubbles can be measured, thus quantifying the enzymatic activity (Bernardelli et 
al 2007). 
2.2.4 Urease test  
The urease enzyme is coded by the ureABC genes and is able to hydrolyze urea, forming two 
molecules of ammonium; this is used by the mycobacteria in the process of biosynthesis 
(Palomino et al 2007). The determination is made by using a medium containing red phenol; 
production of ammonium results in alkalization of the medium with a change in color to 
fuchsia. 
2.2.5 Pyrazinamidase test 
This is an intracellular enzyme codified by the pncA gene which is able to hydrolyze 
pyrazinamide (PZA) in pyrazinoic acid. Some strains present a mutation in the pncA gene 
that generates resistance to PZA, the principal mechanism of resistance in M. tuberculosis to 
this drug. The method of transport of PZA into M. tuberculosis is by passive diffusion, where 
it is converted into pyrazinoic acid through the action of the pyrazinamidase enzyme. Its 
usefulness as a test of identification is based on the differentiation of M. tuberculosis (positive 
pyrazinamidase) from other species of the M. tuberculosis complex (negative 
pyrazinamidase), with the exception of M. canetti which is also positive (Palomino et al 2007, 
Zhang et al 2003). 
2.2.6 Acid phophatase 
The acid phosphatase of some mycobacteria separates the free phenolphthalein from 
phenolphthalein diphosphate using as a substrate of the reaction the magnesium salt 
thymophthalein monophosphate. The appearance of a red color is positive for acid 
phosphatase. The M. tuberculosis species is negative in this test.  
2.2.7 Hydrolysis of polyoxyethylene mono-oleate 
This shows the capability of some species of mycobacteria to separate the oleic acid which is 
esterified in polyoxyethylene monoleate; it is better known commercially and in the 
laboratory environment as “Tween 80”. 
2.2.8 Arylsulfatase test 
The test is based on the capability of some species of mycobacteria, through the activity of 
arylsulfatase which acts on sulfate esters, to release its aryl radical. To confirm the activity of 
the enzyme a color development system should be attached, using phenolphthalein 
disulfate potassium in the culture medium, that is hydrolyzed by the enzyme producing 
free phenolphthalein; in the presence of an alkali, a red color appears when the test is 
positive. Examples of species positive for this test, after three days, are: M. fortuitum and M. 
abcesuss; M. gastri presents a positive reaction only after two weeks.  
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2.2.9 Other phenotypic test 
Tellurite reduction, oxygen preference, utilization of carbon sources, iron uptake, B 
galactosidase. (See figure 1). 
3. Molecular identification of mycobacteria 
The amazing development of biological molecular methods, in the last years, for 
identification of mycobacteria were implemented for clinical and research uses. Different 
molecular approaches developed in research laboratories became speedily in diagnostic test. 
The reference molecular method for identification of mycobateria is the determination of 
sequences of 16S ribosomal DNA, due to this molecule is highly conserved. (Kirschner et al 
1993). The 16S-23S internal transcribed spacer (ITS) sequencing is a supplement to 16S rRNA 
gene sequencing for identification of closely related species (Roth et al 1998). Others 
examples of DNA sequencing assays are, gyrB, and rpoB sequences. The DNA probes used 
in conjunction with culture methods was employed in many countries for identification of 
mycobacteria, examples of this methodologies are, AccuProbe, Line probe Assays, INNO 
LiPA Mycobactera, GenoType Mycobacterium, and GenoType MTBC. Currently, the most 
reported methodology for mycobacterial identification is the polymerase chain reaction 
(PCR) restriction-enzyme analysis, this methods is based on the amplification of a 441.bp 
fragment of the hsp65 gene by PCR and discriminate between all mycobacterial species (M, 
tuberculosis complex species presents the same patrons) (Telenty 1993, Castro et al 2007, 
2010, Torres et al 2010). 
Different molecular typing methods developed and implemented as a result of the 
accelerated development of molecular biology have been useful in various contexts of public 
health and scientific research, among which we can cite: the monitoring of individual 
clinical isolates of species belonging to the M. tuberculosis complex; studies of the 
transmission of tuberculosis (TB) in urban areas with low, medium, and high rates of 
transmission; analysis of recent cases of transmission, or TB cases caused by reactivation, 
reinfection, or mixed diseases; establishment of relationships between remote geographical 
areas; the influence of transcontinental movements of large numbers of tourists; 
determination of the geographical origin of isolates; epidemiological analysis of TB 
outbreaks in closed areas such as prisons, child-care centers, geriatric homes, and 
indigenous communities; the establishment of the epidemiological nexus of cases that are 
the product of contacts with a specific patient; and the identification of the index case 
through a combination of molecular typing techniques.  
As typing techniques, both the spoligotyping and Mycobacterial Interspersed Repetitive 
Units (MIRU) methodologies are the most commonly used tools; they provide a high degree 
of reproducibility of results and every day are reported in more publications that attest to 
their versatility and wide use throughout the world; but it cannot be denied that other 
methodologies exist, which are described below, that have made great contributions in 
typing processes. 
3.1 Typing methods  
The M. tuberculosis genome is markedly homogeneous with 99.9% similarity and identity to 
the 16s rRNA sequence, with M. africanum and M. mungi being species genetically related to 
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the M. tuberculosis complex and presenting few mutations (Niobe-Eyangoh et al 2004, Brosh 
et al 2002). This characteristic has been employed in the development of methodologies that 
permit the differentiation of species of this complex. As an example of the contribution of 
this characteristic in the differential identification of M. tuberculosis isolates, the following 
techniques were initially employed: determination of unusual resistance to drugs; 
serotyping; multilocus enzyme electrophoresis; biochemical heterogeneity, and typing 
through the use of phages, with the last being the standard technique in use until the end of 
the 1980’s, but presenting problems such as the low number of phage types identified and 
the labor intensity associated with this experimental protocol. (Jones et al 1975, 1978, 
Kalndtri et al 2005, Dïaz et al 2003). The genome of the species that comprise the M. 
tuberculosis complex presents occasional recombinations caused by mobile fragments or 
sequences of DNA known as transposons; these are unstable elements potentially capable of 
causing rearrangements through transposition, deletion, inversion, and duplication, since 
they are insertion sequences. These mobile insertion elements are responsible for directing 
the generation of genetic polymorphisms which are commonly employed for discriminating 
among different isolates. In the studies of M. tuberculosis molecular epidemiology the most 
frequently used insertion sequence is IS6110, which is found exclusively in members of the 
M. tuberculosis complex, presenting between 0 – 25 copies which differ in position and 
number. The study of this element soon became an epidemiological milestone and a 
methodology of great clinical contribution (Coros et al 2008, Mostrom et al 2002).  
In this context the clinical isolates of the M. tuberculosis complex that present the same 
genetic pattern are defined as groupings and it is believed that these cases could have been 
caused by a recent infection, being part of the same chain of transmission, as opposed to 
cases of family origin, nosocomial, reinfections, or reactivations. More recently, with 
genomic sequencing of various members of the M. tuberculosis complex, techniques have 
been employed such as: Sequencing of single nucleotide polymorphism (SNP) 
spoligotyping, Fluorescent amplified fragment length polymorphism (FAFLP), and, among 
others. (National TB Controllers Association 2004, Centers for Diseases Control and 
Prevention (CDC) 2006 and 2007, Caminero et al 2001, Shamputa et al 2007, Small et al 1994, 
Kamerbeek et al 1997, Kassama et al 2006, Gibson et al 2008, Kremer et al 2005, Orjuela et al 
2010, Hernandez et al 2010). 
Currently, the methods of molecular typing of members of the M. tuberculosis complex can 
be grouped as (Mostrom 2002, Narayabab et al 2004, Parra et al 2003, and Diaz 2003): 
3.1.1 Genomic methods for DNA studies 
Restriction Fragment Length Polymorphism IS6110 (RFLP IS6110) 
Polymorphic GC rich sequence (PGRS)  
Analysis and pulsed-field gel electrophoresis (PFGE) 
3.1.2 Methods based on the amplification of specific sequences of DNA using the 
PCR  
Spoligotyping, Fast ligation mediated PCR (Flip), Double-Repetitive Element (DRE-PCR), 
MIRU, Ligation Mediated PCR (LM-PCR), Fluorescent Amplified Fragment Length 
Polymorphism (FAFLP), and Single Nucleotide Polymorphism ( SNP). (Steinlein et al 2001,  
www.intechopen.com
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Burgos et al 2004, Varela et al 2005, Reisig et al 2005, Kremer et al 2005, Kasama et al 
2006, Ashworth et al 2008, Rozo et al 2010, Collins 2011, Li et al 2011, Blaschitz et al 
2011).  
3.1.3 Typing methods based on genomic DNA 
3.1.3.1 RFLP IS6110 
Given the current knowledge of the M. tuberculosis genome H37Rv, the use of IS6110 was, 
until recently, the most frequently reported method for discriminating among 
bacteriological clinical isolates of members of the M. tuberculosis complex; a reduction in its 
frequency of use is now observed given new methods such as those based on PCR. The 
RFLP IS6110 technique has certain disadvantages such as: being labor-intensive; slow; 
requiring a large quantity of good-quality DNA (1-2 µg); limited ability to discriminate 
isolates with less than 6 copies of IS6110 (< 6 bands in the RFLP pattern); and difficulty in 
comparing results obtained in different laboratories since an international database does not 
yet exist due to results being reported in patterns and not codes. This molecular marker 
possesses stability of approximately one to three years in patterns of RFLP IS6110, which is 
related to the number of copies present, since a larger number of copies imply a greater 
possibility of transposition, especially among isolates of 8 to 12 copies. In general, studies 
show a high stability in patterns of RFLP IS6110 (Van et al 1991, Gordon et al 1999, Diel et al 
2002, Mostrom et al 2002, Gopaul 2006). 
3.1.3.2 PGRS 
This method has been of great usefulness in typing clinical isolates of members of the M. 
tuberculosis complex that present a low number of copies of the insertion sequence IS6110. 
These repetitive sequences are present in multiple copies through the mycobacterial 
genome; approximately 26 to 30 copies of these repetitive sequences are found per 
chromosome in members of the M. tuberculosis complex. It has a discriminating power very 
similar to that of RFLP, requiring DNA of good quality extracted from cultures of 
approximately 15 days growth in order to conduct the experimental protocol; several weeks 
are needed in order to obtain the pattern of each bacterial isolate in electrophoresis gel 
similar to that obtained through analysis of the IS6110 sequence. It has a low discrimination 
in isolates that possess multiple copies of this genetic marker. (Burgos et al 2004, Rozo et al 
2010). 
3.1.3.3 PFGE 
This method possesses a high power of discrimination, requiring large concentrations of 
DNA with purity and quality; for its implementation it is necessary to make various 
adaptations in the experimental protocol according to the unique requirements of each 
laboratory. The introduction of PFGE has had great impact in the study and investigation of 
the mycobacterial genome, above all in the creation of genomic maps of closely related 
species such as those that comprise the M. tuberculosis complex, thus allowing for the 
establishment of differences through the identification of multiple rearrangements and of 
the nonrandom location of insertion elements (Wolfgang et al 1998). 
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3.1.4 Typing methods based on PCR 
3.1.4.1 Spoligotyping 
The direct repetitive regions of the “Direct Repeat” sequence in members of the M. 
tuberculosis complex are composed of multiple direct variant repetitive sequences, each of 
which is comprised of direct repetitions of approximately 36 pairs of bases separated by 
unique spacer sequences of 35 to 41 pb, generating a large polymorphism which can be used 
in molecular epidemiological studies for the differentiation of species of the M. tuberculosis 
complex. The methodology of spoligotyping is based on PCR which is targeted on a small 
DR sequence sandwiched within a spacer region; a total of 94 sequences have been 
identified, of which 43 are generally used in the genotyping of isolates. All of these can be 
simultaneously amplified using a single primer set. The presence or absence of these 
sequences is determined by hybridization with a set of 43 oligonucleotides derived from M. 
tuberculosis H37Rv. This technique has been shown to be useful in the typing of clinical isolates 
of species of the M. tuberculosis complex, especially in those with less than 6 copies of IS6110, 
and in different clinical samples (Bauer 1999, Doroudchi et al 2000, Parra et al 2003). 
3.1.4.2 Flip 
A rapid method with high reproducibility and great power of discrimination, based on the 
study of the IS6110 sequence. In comparison with the RFLP IS6110 methodology, this 
technique requires small quantities of DNA (1ng) or crude cell lysates. This methodology 
has limited discriminating power in isolates with less than six copies of the IS6110 sequence; 
it gives results in less time than LM-PCR (Reisig et al 2005). 
3.1.4.3 DRE – PCR technique 
A methodology with great power of discrimination that consists in the amplification of 
DNA segments located between the IS6110 sequence or the polymorphic region rich in 
guanine cytosine (PGRS). The DRE-PCR method is based on the number of copies and the 
distance between the repetitive sequences of IS6110 and PGRS; these distances vary among 
the different clinical isolates analyzed, and the variations allow a differentiation with respect 
to the size and number of the amplified fragments of DNA, producing a single pattern band 
for the different strains of M. tuberculosis. It is a method that can be completed using the 
primary culture of the microorganism and the results can be interpreted after eight hours of 
work. One of the limitations of this methodology has been the poor power of resolution of 
the bands procured (Mostron et al 2002).  
3.1.4.4 MIRU 
A typing methodology based on the varible number tandem repeat (VNTR) or MIRU, with a 
power of resolution similar to that produced by RFLP IS6110, has been useful for typing of 
members of the M. tuberculosis complex. The MIRU are short elements of DNA (40 to 100 pb) 
found in tandem repetitions and dispersed in intergenic regions of the genome within 
members of the complex. Given its discriminating power, among the 41 sequences of MIRU 
that have been described, only 12 or 16 of them are frequently reported as genetic markers. 
The clinical isolates that are characterized by this genetic marker are designated with a 12-
digit code corresponding to the number of repetitions in each MIRU locus, thereby forming 
the basis of a system that facilitates global comparison among laboratories (Supply et al 
2000, 2001, Evans et al 2004, Narayanan et al 2004, Gibson et al 2005).  
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3.1.4.5 LM-PCR 
This is a highly reproducible technique that uses a primer directed toward a specific region 
of insertion sequence IS6110, and a second that is targeted to a linker ligated to restricted 
genomic DNA. This methodology requires small quantities of DNA and has a high power of 
discrimination (Prodhom et al 1997, Kremer et al 2005). 
3.1.4.6 FAFLP 
 The FAFLP is a complementary technique for the typing of M. tuberculosis, principally in 
clinical isolates with less than 6 copies of IS6110. It has the limitation of requiring the 
extraction of DNA from the microorganism in growth; subsequently, this is digested with 
EcoRI and Msel restriction enzymes, although some studies report using BamHI and Mspl 
(Mortimer 2001, Sims et al 2002). 
3.1.4.7 SNP 
This methodology is based on the premise that MicroRNAs (miRNA) are thought to play 
important roles in the pathogenesis of diseases. SNPs within miRNAs can change their 
characteristics via altering their target selection and/or expression, resulting in functional 
and/or phenotypic changes. This methodology has produced results similar to those 
obtained from RFLP IS6110 and spoligotyping. This technique generates a binary code that 
permits the creation of a comparative database of different studies (Li et al 2011).  
3.1.4.8 Other methodologies 
Other methodologies have been developed for the identification and study of mycobacteria 
such as “in house” PCR (Puerto et al 2007), but statistics have not been reported that would 
permit an extensive evaluation of these methodologies. There is a large variation among the 
reported studies which precludes any conclusions regarding their contributions.  
4. Recent promising technologies for the detection of M. tuberculosis 
4.1 Urinary antigen detection 
This method is based on the direct detection of lipoarabinomannan (LAM) in urine, when 
the mycobacteria are metabolically active; accordingly, this glycolipid is found in the urine 
of patients with active turberculosis. This antigen can be detected through an ELISA test and 
the determination presents high ranges of sensitivity (from 38 to 51%) and of specificity, 
close to 89% (Daley et al 2009, Lawn et al 2009, Mutetwa et al 2009, Reither et al 2009, Deng 
et al 2011). 
4.2 Volatile markers 
Through chromatographic techniques, various molecules or organic compounds have been 
identified in human clinical samples with the objective of showing their potential use as 
markers in the surveillance of illnesses. The volatile organic compounds (VOCs) patterns 
identified in the M. tuberculosis specie through sputum samples allow, through the use of an 
electronic nose based 14-sensor conducting polymer array, the performance of in vitro and 
in situ studies. Reports indicate that this methodology identifies 100% of positive M. 
tuberculosis cultures from among others and were able to discriminate between sputum 
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containing either M. tuberculosis alone, or a mixed infection. The technique is commonly 
referred to as “breath testing,” with the great advantage of not being an invasive procedure; 
in a small study it distinguished between patients with a positive sputum culture from those 
with a negative sputum culture (Pavlou et al 2000, 2004, Buszewski et al 2007, Phillips et al 
2007). 
4.3 Bead-based methods 
This method is based on the application of monoclonal antibodies to nano magnetic beads in 
order to identify the bacillus. Microsciences Medtech Ltd. (London, United Kingdom) 
developed a kit of beads coated with a chemical ligand that binds to mycobacteria present in 
the sputum of patients; the linkage is evident after coloring the preparation and observing it 
through a fluorescent microscope. Alternative diagnostic techniques have been developed 
using nanoparticles coupled to PCR, while other methodologies employ monoclonal anti-
BCG antibodies. This methodology can be used for detection and identification of M. 
tuberculosis (Kluge et al 2008, Lee et al 2009). 
4.4 Simplified smart flow cytometry (S-FC) 
Following the use by many researchers of flow cytometry to count CD4 T cells, the S-FC has 
been recently proposed for arriving at a rapid diagnosis of active TB among Human 
Immunodeficiency Virus (HIV) negative patients and those with the TB/HIV coinfection. 
The S-FC is considered to be of great use when a sputum sample cannot be obtained, or 
among patients with negative sputum, with the recommendation that it be combined with 
microbiological procedures (Castiblanco et al 2006, Breen et al 2007, Streitz et al 2007, 
Janossy et al 2008).  
4.5 Broad nucleic acid amplification-mass spectrometry 
The integration of advances in various technologies such as the technique of analysis and 
separation of masses, bioinformatics, and ionization techniques linked to mass 
spectrometry, has facilitated their application in the identification and characterization of 
pathogens. The successful identification of M. tuberculosis complex through the pattern of its 
mycolic acids has been achieved through the use of Electrospray ionization-tandem mass 
spectrometry (ESI-MS). Other similar methodologies developed by Abbott Laboratories 
include the IBIS T5000 which is based upon the amplification of genome sequences of the 
pathogen linked to mass spectrometry (Ecker et al 2008, 2009, Ho et al 2010, Eshoo et al 2010, 
Grant et al 2010).  
5. Detection of drug susceptibility testing 
The increase in TB cases has been accompanied by a growth in the number of patients with 
isolates of resistant M. tuberculosis, thereby confirming TB as a grave, world-wide public 
health problem. The situation becomes even more complex with the association of M. 
tuberculosis resistant bacilli with HIV, making control more difficult (Bentwich et al 2000, 
Castiblanco et al 2006, Lemus et al 2004, and World Health Organization (WHO) 2009).  
Multidrug-resistant TB (MDR TB), defined as a combined resistance to two first-line 
medications, isoniazid (INH) and rifampicin (RIF), attained a global level of 500,000 cases in 
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the year 2007 and is expected to continue to increase. According to WHO, 85% of these cases 
are concentrated in 27 countries The clinical significance of resistance has been defined as the 
in vitro growth of the microorganism in the presence of the critical concentration of the drug 
used in treatment, which should be equal or superior to 1% of the growth of the 
microorganism in the absence of the drug. The critical concentration of a drug is the 
concentration that inhibits the growth of most wild type within a population without affecting 
the growth of resistant cells that might be present (Kent et al 1985, Woods et al 2007). 
The problem of M. tuberculosis resistance appears when the resistant mutants that naturally 
occur in the microbial population are selected as result of inadequate administration of 
treatment (irregular administration of dosages, poor absorption, or an inadequate treatment 
plan) (Parson et al 2004). 
When a diagnosis is made of a type of resistance to first-line medications such as INH, RIF, 
ethambutol (EMB), streptomycin (SM), and PZA, the WHO recommends treatment plans that 
should be adjusted based upon the pattern of resistance identified in the microorganism and 
each patient’s particular state of health. Second-line medications include: aminoglycosides, 
cycloserine, capreomycin, fluoroquinolones, and para aminosalicylic acid. These treatment 
plans are prolonged in comparison with those of the first-line, with increased costs and 
toxicity, resulting in reduced patient compliance with treatment. When second-line treatment 
plans are not adequately administered, extensively drug-resistant TB (TB XDR) will probably 
appear, which is defined as TB MDR with greater resistance to any fluoroquinolone and to at 
least one of the three injectable medications (amikacin, kanamycin, or capreomycin) (Zumia et 
al 2001,Gillespie 2002, Raviglione et al 2007, 2004, 2003, 2006, 2007, 2008). 
The treatment of TB, compared with that used to cure other infectious diseases, has some 
differences due to the particular physiological characteristics of M. tuberculosis, such as 
generation time and the capacity to enter into long periods of latency with minimal 
metabolic activity. In the process that arises from the interaction between the bacteria and 
the host’s defenses, populations of bacilli are identified that are differentiated based upon 
location, metabolic activity, or velocity of multiplication. Characteristics, therefore, vary 
depending upon location. For example, when located within pulmonary cavities, they 
actively multiply; as opposed to being situated in the interior of macrophages where 
reduced pH and oxygen induce a physiology approximating a state of latency; or, if found 
within the site of necrosis, they are occasionally able to replicate. Due to the characteristics 
of the bacillus and the interaction with the host, various effective drugs are used, as 
appropriate, in the treatment of TB for each of the bacterial populations. Another 
fundamental aspect in the selection and study of drugs used in the treatment of TB involves 
the study of the cell structure of the microorganism, in which the most studied has been the 
bacterial cell wall complex, being hydrophobic, with little permeability, thereby precluding 
the entry of many therapeutic alternatives (Wayne 1974, Guillespi 2002, Coll 2003, Parson et 
al 2004, De Rossi et al 2006). 
INH,RIF, SM, EMB and PZA are first-line medications for their efficacy in bactericidal or 
bacteriostatic activity, having less adverse effects than other antimycobacterial medications, 
as opposed to second-line drugs such as aminoglycosides, polypeptides, fluoroquinolones, 
ethionamide, cycloserine, and para aminosalicylic acid.  
Some characteristics of first- and second-line medications used in the treatment of TB are 
described below in table 1: 
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Nature of 
compound
Administration 
way
Mechanism of action Daily dose 
Actividad 
microbiana
Susceptible 
population
Pharmacological 
interactions
Side effects
7H10 solid 
medium
INH Synthetic Oral
Inhibition of mycolic acid 
synthesis
5mg/kg Bactericidal
Active and 
dormant bacilli
Fenitoína
Hepatotoxic, peripheral 
neuropathy, seizures
0.2; 1.0
RIF Semisynthetic Oral
Inhibition of transcription by 
interacting with RNA polymerase
10mg/kg Bactericidal All population
Inhibe anticonceptivos 
orales, Quinidina.
Hepatotoxic, gastric 
intolerance, 
hypersensitivity
1.0
EMB Synthetic Oral Affects cell wall biosynthesis 20mg/kg Bacteriostatic Active bacilli ND
Optic neuritis, alopecia, 
hypersensitivity
5.0; 10.0
PZA Synthetic Oral
Affects the membrane 
potential for bioaccumulation
25mg/kg Bactericidal
Persistant and 
dormant bacilli
ND
Arthritis, dermatitis, 
hepatotoxicity,          
gastrointestinal disorders
NA
SM
Natural 
(Streptomyces 
griseus)
Parenteral Blocking RNA translation 15mg/kg Bactericidal Active bacilli
Neuromuscular bloking 
drugs, cross resistance 
with capreomycin
Nephrotoxicity,          
ototoxicity
2; 10
Amikacin Semisynthetic Parenteral Inhibition of protein synthesis 15mg/kg Bactericidal Active bacilli
Neuromuscular bloking 
drugs
Lesion of cranial pair VIII, 
nefrotoxicity
4.0
Capreomycin
Natural 
(Streptomyces 
capreolus )
Parenteral Inhibition of protein synthesis
15-30mg/kg until 
1g
Bacteriostatic Active bacilli
Neuromuscular bloking 
drugs
Lesion of cranial pair VIII, 
nefrotoxicity
10.0
Ciprofloxacin
Synthetic molecule 
derived of carbonic 
acid
Oral and parenteral Direct inhibition of DNA gyrase
150mg/kg until 
12g
Bactericidal Active bacilli
Cross-resistance with 
other quinolones
Gastrointestinal disorder; 
CNS; hypersensitivity
2.0
Ethionamide Syntetic Oral
Inhibition of mycolic acid 
synthesis
15-30mg/kg until 
1g
Bacteriostatic
Active and 
dormant bacilli
ND
Gastrointestinal disorder; 
hepatotoxic
5.0
Kanamycin
Natural 
(Streptomyces 
kanamyceticus )
Parenteral Inhibition of protein synthesis
15-30mg/kg until 
1g
Bactericidal Active bacilli
Neuromuscular bloking 
drugs
Lesion of cranial pair VIII, 
nefrotoxicity
5.0
Levofloxacin
Synthetic molecule 
derived of carbonic 
acid
Oral and parenteral Direct inhibition of DNA gyrase 500mg Bactericidal
Active and 
dormant bacilli
Cross-resistance with 
other quinolones
Tendinitis, neurotoxicity, 
intestinal disorders, rash, 
photosensitivity.
2.0
Cycloserine
Natural 
(Streptomyces 
garyphalus )
Oral
Inhibition of essential pyridoxal 5′-
phosphate (PLP)-dependent 
enzymes.
10-20mg/kg until 
1g
Bacteriostatic 
and bactericidal
Active and 
dormant bacilli
Alcohol
Neurotoxicity, psychosis, 
seizures, depression
25-30 ≤
Ofloxacin
Synthetic molecule 
derived of carbonic 
acid
Oral Direct inhibition of DNA gyrase 600-800mg Bactericidal Active bacilli
Cross-resistance with 
other quinolones
Gastrointestinal disorder; 
CNS; hypersensitivity
2.0
Para-aminosalicylic 
acid
Synthetic molecule 
derive from 
salicilic acid
Oral
Antagonist in the synthesis 
of folate from all mycobacteria
200mg/kg Bactericidal Active bacilli ND
Gastrointestinal disorder; 
hepatotoxic
2.0
F
ir
s
t 
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e
S
e
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n
d
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e
Drug
References: Svensson et al 1982,Pfyffer et al 1999, Caminero 2003, Coll 2003, Cohenet al 2003, Zh
et al 2007, Boldú et al 2007, Loether et al 2010,Cremades et al 2011, Pholwat et al 2011, pholwat e
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Determining the probability that M. tuberculosis will develop spontaneous resistance to two 
drugs used in treatment can be established through the sum of probabilities; for example, a 
probability exists of 1x106-1x108 of a combined resistance to INH and RIF, being equal to a 
total probability of 1x1014. In the process of the development of TB, the total number of 
possible bacilli in the patient, including cases of chronic cavitary disease, seldom results in 
this quantity of bacilli (1014). Consequently, the natural development of bacilli resistant to 
two medications is infrequent; therefore, it is assumed that in the majority of cases, this type 
of resistance is due to previous exposure to the medications (Long 2000).  
Some data suggest that about 17% of new TB cases in a zone of high incidence evidence 
multiple infections, causing discordance and difficulty in the interpretation of tests and in 
patient management. The expansion of isolates of resistant M. tuberculosis is a concern and 
creates urgency in the implementation of effective diagnostic measures and control, focusing 
hopes on the development of a new vaccine, diagnostic methods, and effective alternative 
therapies (Zumia et al 2001, Richardson et al 2002, Gandhi et al 2006, Palomino et al 2007, 
WHO 2006, Raizada et al 2009). 
5.1 Diagnostic methods of susceptibility 
A great variety of methodologies exist for determining the susceptibility of M. tuberculosis to 
medications, among which include standard tests showing the growth of bacillus, such as 
the method of multiple proportions and BACTEC MIGT 960. Other methods of great impact, 
and experiencing growing implementation at a global level, are those based on the 
amplification of nucleic acids through PCR, designated as genotypic methods (Wilson M. et 
al 2011). Some of these include microarrays of DNA, and solid- phase hybridization, among 
others. The aforementioned methodologies possess excellent percentages of sensitivity and 
specificity; however, they vary in the time required to obtain results, cost, and technical 
complexity, thus complicating their large-scale use, especially in countries with limited 
resources that employ conventional methods. Rapid phenotypic techniques have recently 
been endorsed by WHO, and they constitute good solutions for a fast and timely diagnosis 
of susceptibility compared with standard methodologies, and with the cost and 
infrastructure required for molecular techniques (Canettii et al 1963, 1969, Siddiqi et al 1981, 
Telenti et al 1993, Abate et al 1998, Palomino et al 2002, 2005, Mitchison 2005,Lakshmi et al 
2006). 
5.1.1 Phenotypic methods 
Phenotypic methods are extensively used and a wide variety of studies are available that 
establish their principal advantages and disadvantages. They begin with the cultivation of 
isolates of M. tuberculosis obtained from clinical samples processed in an egg- or liquid-
based culture medium, some of which can include antibiotics, which are used for direct 
determination (observation of the microorganism) or indirect (for example, through color 
reactions) of the growth of the microorganism and subsequent identification of the 
resistance of the microorganism through its growth in the presence of anti-TB drugs.  
5.1.1.1 Mycobacteria Growth indicator Tube (MGIT BACTEC) 
Although various conventional phenotypic methods have been employed in the study of the 
susceptibility of M. tuberculosis, the most frequently reported, using solid media, are: the 
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multiple proportions method; the ratio of resistance and absolute concentrations; and the 
standard, automated radiometric BACTEC method that, as opposed to the others, uses a 
culture in liquid medium and the tube growth indicator method. Modifications to the 
BACTEC system have been adopted in order to avoid the use of radioactive material; these 
have consisted of using the principle of detecting oxygen consumption and recording the 
emission of fluorescent signals as a product of the reaction in each test, which is detected 
and controlled from the interior of the equipment coupled to software algorithms. The 
system interprets as resistant all cultures with growth equal or greater than that of the tube 
used as a control in the test (Pffyer et al 1997, 1999, Heifets et al 2000, Lin et al 2009, Yu et al 
2011). 
5.1.1.2 The Trek Diagnostic System Inc  
This method measures the growth of mycobacteria through changes of pressure that occur 
in the space between the liquid medium and the cap of the tube where the reaction occurs. 
Results are obtained in approximately three days (Woods et al 2007). 
5.1.1.3 The MB/BacT Alert instrument (bioMérieux) 
This system emits results from an isolate of M. tuberculosis when the bottle that contains the 
microorganism and the drug is positive before the control tube. The result is obtained 
through measurement of carbon dioxide released to the medium, detected by a sensor 
located at the bottom of the bottle used in the test (Siddiqi et al 2006, Woods et al 2007, Lin et 
al 2009). 
5.1.1.4 The multiple proportions method 
This method determines the number of mutants resistant to each drug, establishing a 
relation between the numbers of bacilli that grow in a solid medium with antibiotic as 
compared with the number of bacilli that grow in a medium without antibiotic. The 
methodology used with solid medium evaluates the susceptibility of M. tuberculosis to first- 
and second-line medications. Frequently, the method employed uses the LJ culture medium 
and results are obtained in 21 days, or before, if there are indications of growth (Cannetti et 
al 1963, 1969, Heifets 2000, WHO 2004, Fisher 2002, Clinical and Laboratory Standards 
Institute 2003, Woods et al 2007, Pfyffer 1997, 2007).  
Currently, BACTEC MGIT (version 960 or 320) and the multiple proportions method are 
considered as “gold standard” for the diagnosis of TB susceptibility to first- and second-line 
medications (Pino et al 1998).  
As mentioned previously, phenotypic methods of relatively recent implementation now 
exist, and are noted for having succeeded in establishing a group of non-conventional 
phenotypic techniques that have been postulated as good diagnostic alternatives for the 
susceptibility of M. tuberculosis depending upon their performance given the particular 
situations in which they are used.  
5.1.1.5 The diagnosis of TB and drug resistance with mycobacteriophages 
This group of methodologies offers rapid results, low cost, and uses only viable cells, 
thereby differing from molecular methodologies. Two types of tests that use 
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mycobacteriophages have been documented: the phage amplified biological assay (phaB) 
and the luciferase reported phages (LRPs). Both methodologies study the capacity of a 
clinical isolate of M. tuberculosis to harbor an infectious mycobacteriophage and to permit its 
replication (Albert 2001, Butt et al 2004, Pai et al 2005, and Kalantri et al 2005).  
5.1.1.5.1 The PhaB 
The PhaB determines the protection and amplification of a phage by mycobacteria in clinical 
specimens (Eltringham et al 1999). The methodology consists of: 
1. Adding phages to the decontaminated clinical sample in order to infect the bacilli 
present in the samples; 
2. Adding a viricidal solution (ammonium ferrous sulfates) that destroys the non-infective 
phages.  
3. Initiating a lytic cycle of the bacilli for the replication of phages; this phase terminates 
with the release of the phages to the Medium. 
4. Released phages added to a cell sensor (M. smegmatis) to produce plaques; the 
formation of plaques occurs if the sample is positive (Albert et al 2004).  
5.1.1.5.2 LRPs 
The LRPs are phages harboring the firefly luciferase (flux) gene, which produces visible light 
when expressed in the presence of lucifering and cellular ATP (Hazbon 2004). The LRPs 
behave as molecular vectors of the flux gene that encodes for firefly luciferase in the interior 
of M. tuberculosis. Once this genetic information has been incorporated within the bacterial 
chromosome, it is expressed, and there is availability of ATP and luciferin, photon emissions 
are produced that are detected by a photographic film in a luminometer. The registering of 
light emitted indicates the viability of the bacilli (Riska et al 1997, 1998, 1999, Carriere et al 
1997, 2003, Bardarov et al 2003).  
5.1.1.6 The E-Test 
The E-Test determines the pattern of susceptibility of M. tuberculosis through growth 
inhibition halos around strips impregnated with known concentrations of different drugs. 
Solid medium is used in Middlebrook 7H10 agar plates; the microorganism to be studied 
should be viable and concentrated in the solution that will be used for inoculation of the 
medium (Heifets et al 1999, Djiba et al 2004). 
5.1.1.7 The colorimetric methods 
These methodologies are simple and coupled to oxidation-reduction reactions that employ 
different indicators. Alamar blue salt is used in the case of REMA and MABA, and bromide 
3 (4,5-dimethylthiazol-2-i)-2,5-diphenyltetrazolium, or MTT in the case of TEMA. 
Fundamentally, the result is obtained through observing a change of color, proportional to 
the number of viable mycobacteria in the test. TEMA was implemented in 1983 for the study 
of cellular proliferation and was subsequently utilized to evaluate the viability of 
microorganisms such as Staphylococcus aureus and Listeria monocytogenes; it has been 
extensively used in the study of M. tuberculosis resistance. The resulting color in this 
methodology changes from yellow to purple from the production of insoluble crystals of 
formazan that can be quantified by spectrophotometry, or a qualitative interpretation can be 
made by observing the change of color. The methodology provides results within 7 to 9 days 
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in the model proposed by Abate and Mishana for the rapid detection of RIF resistance. The 
advances of this methodology have included the study of clinical samples applied directly 
to the test, reporting good values of sensitivity and specificity, close to 100%, for sputum 
samples. This test permits the determination of the susceptibility of M. tuberculosis to first- 
and second-line drugs in establishing the diagnosis of MDR and XDR TB (Mossmann 1983, 
Abate et al 1998, Palomino et al 1999, 2002, Morcillo et al 2004, WoldeMeskel et al 2005, 
Montoro et al 2005, Palomino et al 2007, CDC 2007). The REMA test employs resazurin as an 
indicator, with an increase in the production of NADPH/NADP, FADH/FAD, 
FMNH/FMN, and NADH/NAD during multiplication of the bacilli to be studied. The 
viability of the microorganism is evidenced by the change from blue to pink in the indicator 
color. This test shows values of sensitivity and specificity exceeding 90% in the evaluation of 
drugs such as RIF and INH, as well as for second-line drugs. Some reports indicate difficulty 
in the interpretation of results due to intermediate tones in the change of indicator color 
(BioSource International, O´brien et al 2000, Maeda et al 2001,Palomino et al 2002, Martin et 
al 2003, Montoro et al 2005, Rivoire et al 2007). 
5.1.1.8 Microscopic-observation drug-susceptibility (MODS) 
The MODS are used in various countries with TB MDR problems and permit the rapid 
observation of the growth of M. tuberculosis in culture media with the different first- and 
second-line drugs employed in the treatment of TB. One of those methods is MODS, that 
uses an inverted microscope to view the growth of the microorganism. Other methods 
include a thin layer of agar (TLA) and the HSTB agar method, that use special, transparent, 
solid culture media, permitting the early observation of the growth of the microorganism 
with the aid of a conventional microscope (Caviedes et al 2000, Heifets et al 2003, Mejia et al 
2004, Robledo et al 2008).  
5.1.1.9 The Nitrate Reductase Assay (NRA) or Griess Method 
The NRA is based upon the characteristic expressed by mycobacteria to reduce nitrate to 
nitrite, is a rapid method used in the TB control programs of various countries for the 
evaluation of the susceptibility of M. tuberculosis; this is coupled to processes that permit 
observation of color change. The test employs the LJ solid medium (Angeby et al 2002, 
lemus et al 2006, Palomino et al 2007).  
5.1.2 Genotypic methods 
The genotypic molecular methods for the diagnosis of the susceptibility of M. tuberculosis to 
drugs used in the treatment of TB are based on genetic determinants of resistance, requiring 
for its development the amplification of specific segments of DNA, and the identification of 
point mutations in the amplified products, thereby permitting the detection of resistance to 
medications (Cockerill et al 1999, Telenti et al 1993, Palomino 2005, Fluit et al 2011). 
Compared to phenotypic methods, these methodologies have the advantage of not requiring 
the previous growth of the microorganism, with results being obtained in a short time (24 to 
48 hours). The following is a description of some methods: 
5.1.2.1 DNA sequencing 
This methodology is the best and most accurate method for the detection of previously 
known mutations and for the identification of new mutations. It is the “gold standard” 
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method. It is very effective for detecting mutations to RIF in M. tuberculosis by amplification 
of a single target of study in contrast to studies of various genes involved in resistance. 
5.1.2.2 DNA microarrays 
This methodology is based on hybridization and allow for the simultaneous analysis of a 
large quantity of gene segments involved in resistance. The segments amplified by PCR are 
marked with a fluorescent substance and hybridized with probes attached to a solid phase. 
Consistent results have been reported for this methodology in the study of resistance to RIF 
(rpoB gene) and genes implicated in resistance to other drugs such as: KatG, inhA, rpsL, and 
gyrA. The wide-scale implementation of this methodology has been limited due to the 
required technical expertise of the operator and the sophisticated equipment. The QIAplex 
test (Qiagen) system has been recently developed which detects 24 mutations in the katG, 
inhA, rpoB, rrs, rpsL, and embB genes (Gegia et al 2008). 
5.1.2.3 The Line Probes Assay (LPA) 
This method is employed to identify M. tuberculosis and determine resistance to RIF, 
identifying mutations in a specific region of the rpoB gene through amplification of this 
segment using PCR-based reverse hybridization, and using biotin in the test. These labeled 
products of PCR hybridize with immobilized probes coupling to a color development 
system that permits the subsequent analysis of resulting color patterns. This test detects four 
of the most frequent mutations in the rpoB gene arguing that 75% of the clinical isolates 
resistant to RIF have one of these four mutations. The method can be developed from 
clinical samples with results obtained in 48 hours or less (De Beenhouwer et al 1995, 
Somoskovi et al 2003, Ramaswamy et al 1998, WHO 2007, Ando et al 2011).  
5.1.2.4 Single-strand conformation polymorphism (SSCP) 
This methodology detects specific mutations in the region of DNA under study, through the 
difference in patterns of movement of polyacrylamide gels. The region of the gene involved 
in resistance should be amplified by PCR and then denatured until two completely 
separated DNA strands are obtained. These denatured strands migrate by electrophoresis 
permitting the detection of mutated sequences by the migration pattern, as compared with 
that which has been established for the wild strain. This methodology has been employed in 
studies of resistance to RIF; it has not been practical for the investigation of other drugs as it 
requires the study of various genes involved in resistance to those medications (Kim et al 
1997).  
5.1.2.5 Real – time PCR or molecular beacons 
This methodology is reported as the most rapid methodology among those most frequently 
used. This technique includes the use of a probe that is designed in the form of a loop that 
possesses a sequence that is complementary with the sequence of the gene under study, and 
with the appearance of a fluorescent moiety in one of its extremities. When the probe locates 
the complementary sequence, hybridization occurs with the emission of fluorescence; the 
signal is detected and monitored by the associated system. This methodology is highly 
sensitive and specific; only one change in the sequence under study prevents hybridization, 
allowing the identification of point mutations. This is a closed system; therefore, minimizing 
the possibilities of amplification of contaminants. For the study of resistance to RIF, a set of 
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five beacons has been designed, which includes the study of the entire rpoB region in only 
one test. Results are provided in three hours using this methodology, detecting a minimum 
of two bacilli present in the sample. The test includes the study of genes such as katG, inhA, 
oxyR-ahpC, and kasA (Cockeril 1999, Fluid et al 2001, Piatek et al 1998, 2000, Torres et al 2000, 
De Viedman 2003). 
5.1.2.6 Fluorescence resonance energy transfer (FRET) probes 
The FRET is a widely-studied, well-established methodology referred to as “light cycler 
probes.” It is highly specific in identifying mutations in real-time PCR tests. The test permits 
the detection of RIF and INH resistance in less than two hours with the advantage of 
facilitating the study of large gene segments involved in resistance (Garcia et al 2002, Torres 
et al 2003).  
5.1.2.7 Other methodologies 
Other methodologies have been developed for the study of resistance to drugs used in the 
treatment of TB such as “in house” PCR, but statistics have not been reported that would 
permit an extensive evaluation of these methodologies. There is a large variation among the 
reported studies which precludes any conclusions regarding their contributions.  
5.1.2.8 Amplification refractory mutation system (ARMS) 
This methodology uses a set of primers, one of which should hybridize with the mutation 
site; in the absence of this, there is not a place for the amplification of the gene involved in 
resistance; therefore, the band of the expected product is not observed in the electrophoresis 
gel. This methodology is used for the study of mutations in the rpoB, katG y, and embB genes 
with good results (Mokrousov et al 2002, Fan et al 2003). 
5.1.2.9 Branch migration inhibition (BMI) 
The BMI requires two reactions from PCR, one using DNA from a known strain, and the 
other using DNA which is the object of study, using a primer labeled with digoxigenin or 
biotin. This test has been used to study resistance to RIF and PZA; a disadvantage is the 
identification of silent mutations that conflict with findings reported by phenotypic methods 
(Lishanski et al 2000, Lyiu et al 2000).  
6. Conclusion 
The implications of the processes in which mycobacteria participate are diverse and 
documented but there is a lack of knowledge concerning many of their characteristics. 
Health, environment, industry, and research are involved with these mycobacterial species 
in order to advance or improve their processes, verify their findings, or confirm their 
suspicions. In each of these fields the principal objectives are the detection, identification, 
and characterization of the species of the Mycobacterium genus; only the knowledge of its 
biological characteristics together with the availability of methods for its study can help us 
to achieve a complete documentation. The disciplined, periodic and timely revision of the 
biology, tendencies, innovations, and discoveries regarding this microbial genus should 
prove to be the best allies of academics, researchers and the general community in 
addressing any situation that involves mycobacteria in its processes.  
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